Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride

Applied Clay Science

Volumn 99, Issue , 2014, Pages 42-47

  Jain, Shilpa ^a   Datta, Monika ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Extended release; Montmorillonite nanocomposites; PLGA; Venlafaxine hydrochloride

Indexed keywords

CLAY MINERALS; DRUG DELIVERY; DRUG PRODUCTS; EMULSIFICATION; NANOCOMPOSITES; SYNTHESIS (CHEMICAL);

CONTROLLED RELEASE FORMULATIONS; DOUBLE EMULSION-SOLVENT EVAPORATION; DRUG DELIVERY VEHICLES; EXTENDED RELEASE; MONTMORILLONITE-NANOCOMPOSITES; MONTMORILLONITES (MT); PLGA; VENLAFAXINE;

COPOLYMERS;

DRUG; EMULSION; EVAPORATION; MONTMORILLONITE; NANOTECHNOLOGY; PARTICLE SIZE; SOLVENT;

EID: 84920873631     PISSN: 01691317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clay.2014.06.006     Document Type: Article

References (53)

1. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92:343-1355.
2. Aguzzi P.C., Viseras C., Caramella C. Use of clays as drug delivery systems: possibilities and limitations. Appl. Clay Sci. 2007, 36:22.
3. Ajit I., Senthil A., Rahul B., Narayanaswamy V.B. Formulation and evaluation of venlafaxine hydrochloride mucoadhesive buccal tablets. Int. J. Pharm. 2012, 3:226-231.
4. Anil G., Satyanarayana T., Kumar P.S., Pavani S., Raju B.H.C.H.N., Mohideen S. Formulation and evaluation of gastro retentive floating tablets of venlafaxine hydrochloride. J. Pharm. Ind. Res. 2011, 1:76-82.
5. Aronhime J., Dolitzky B.Z., Nisnevish, G., Wizel, S., 2002. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof. US patents US20020143211 A1.
6. Artzner F., Geiger S., Olivier A., Allais C., Finet S., Agnely F. Interactions between poloxamers in aqueous solutions: micellization and gelation studied by differential scanning calorimetry, small angle X-ray scattering, and rheology. Langmuir 2007, 23:5085-5092.
7. Bhosale U.V., Devi V.K., Choudhar S. Development and in vitro-in vivo evaluation of oral drug delivery system of acyclovir loaded PLGA nanoparticles. Int. J. Drug. Deliv. 2013, 5(3):331-343.
8. Broquet K.E. Status of treatment of depression. South. Med. J. 1999, 92:846.
9. Chen Y., Zhou A., Liu B., Liang J. Tramadol hydrochloride/montmorillonite composite: preparation and controlled drug release. Appl. Clay Sci. 2010, 49:108-112.
10. Danhier F., Ansorena E., Silva J.M., Coco R., Préat A.L.B.V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, 161:505-522.
11. Das P.R., Nanda R.M., Behara A., Nayak P.L. Gelatin blended with nanoparticle cloisite30B (Mt) for control drug delivery of anticancer drug paclitaxel. Int. Res. J. Biochem. Bioinforma. 2011, 1:35-42.
12. Depan D., Kumar A.P., Singh R.P. Cell proliferation and controlled drug release studies of nanohybrids based on chitosan-g-lactic acid and montmorillonite. Acta Biomater. 2009, 5:100.
13. Doddayya H., Patil S.S., Kaledhele A., Udupi R.H., Reddy S.R., Kumar P. Effect of gum rosin and ethyl cellulose on in vitro release of venlafaxine hydrochloride from hydrophilic matrix tablets. Int. J. Pharm. Biol. Arch. 2011, 2:980-988.
14. Dong Y., Feng S.S. Poly (D, L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:6068-6076.
15. Entsuah R., Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol. Bull. 1997, 33:671-676.
16. Eupen J.Th.H., Westheim R., Deija M.A., Meekes H., Bennema P., Vliega E. The solubility behaviour and thermodynamic relations of the three forms of venlafaxine free base. Int. J. Pharm. 2009, 368:146-153.
17. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 2009, 30:3297-3306.
18. Harrison C.L., Ferrier N., Young A.H. Tolerability of high-dose venlafaxine in depressed patients. J. Psychopharmacol. 2004, 18:2,200-2,204.
19. Haskins J.T., Moyer J.A., Muth E.A., Sigg E.B. Wy-45, 881 and ciramadol inhibit locus coeruleus neuronal activity. Eur. J. Pharmacol. 1985, 115:139-146.
20. Hosseini M. Application of UV-spectrophotometry and HPLC for determination of venlafaxine and its four related substances in pharmaceutical dosage forms. Turk. J. Pharm. Sci. 2011, 8:91-104. (http://www.drugs.com/venlafaxine.html).
21. Iliescu R.I., Andronescu E., Voicu G., Ficai A., Covaliu C.I. Hybrid materials based on montmorillonite and citostatic drugs: preparation and characterization. Appl. Clay Sci. 2011, 52:62-68.
22. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
23. Jiang W.L., Gupta R.K., Deshpande M.C., Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 2005, 57:391-410.
24. Joshi G.V., Patel H.A., Kevadiya B.D., Bajaj H.C. Montmorillonite intercalated with vitamin B1 as drug carrier. Appl. Clay Sci. 2009, 45:248-253.
25. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 2002, 82:189-212.
26. Keller M.B. The long-term treatment of depression. J. Clin. Psychiatry 1999, 60:41-45.
27. Klamerus K.J., Maloney K., Rudolph R.L., Sisenwine S.F., Jusko W.J., Chiang S.T. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J. Clin. Pharmacol. 1992, 32:716-724.
28. Lee J.S., Chae G.S., Kun T.A., Khang G. Preparation of 5-fluorouracil-loaded poly(l-lactide-co-glycolide) wafer and evaluation of in vitro release behaviour. Macromol. Res. 2003, 1:183-188.
29. Leon A.C., Solomon D.A., Li C., Fiedorowicz J.G., Coryell W.H., Endicott J., Keller M.B. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J. Clin. Psychiatry 2011, 72(5):580-586.
30. Liu Y., Sun Y., Sun J., Zhao N., Sun M., He Z. Preparation and in vitro/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets. Int. J. Pharm. 2012, 426:21-28.
31. Madurai S.L., Joseph S.W., Mandal A.B., Tsibouklis J., Reddy B.S. Intestine-specific, oral delivery of captopril/montmorillonite: formulation and release kinetics. Nanoscale Res. Lett. 2011, 6(Suppl. 15).
32. Miechel L.T.Z., Gerard H.M.E., Dirk W.G., Jan F.J. In vitro degradation of nanoparticles prepared from polymers based on dl-lactide, glycolide and poly(ethylene oxide). J. Control. Release 2004, 100:347-356.
33. Mirakabad F.S.T., Koshki K.N., Akbarzadeh A., Yamchi M.R., Milani M., Zarghami N., Zeighamian V., Rahimzadeh A., Alimohammadi S., Hanifehpour Y., Joo S.W. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac. J. Cancer Prev. 2014, 15(2):517-535.
34. Nair L.K., Jagadeeshan S., Nair S.A., Kumar G.S.V. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int. J. Nanomedicine 2011, 6:1685-1697.
35. NHS north yorkshire, York PCT Service Specification, Venlafaxine Formulations, Approved Medicines and Technologies Board 2011.
36. Nunes C.D., Vaz P.D., Fernandes A.C., Ferreira P., Romao C.C., Calhorda M.J. Loading and delivery of sertraline using inorganic micro and mesoporous materials. Eur. J. Pharm. Biopharm. 2007, 66:357-365.
37. Olad Ali Advances in Diverse Industrial Applications of Nanocomposites, Chapter 7 2011, 113-138. Intech, India. 1st edition.
38. Olver J.S., Burrows G.D., Norman T.R. Third-generation antidepressants: do they offer advantages over the SSRIs?. CNS Drugs 2001, 15:941-954.
39. Patel H.A., Shah S., Shah D.O., Joshi P.A. Sustained release of venlafaxine from venlafaxine-montmorillonite-polyvinylpyrrolidone composites. Appl. Clay Sci. 2011, 51:126-130.
40. Raghvendra, Saraswathi R. Nano-clays and drug delivery system: an overview. Int. J. Pharm. World Res. 2012, 3(3):1-16.
41. Rodrigues L.A.S., Figueiras A., Veiga F., Freitas R.M., Nunes L.C.C., Filho E.C.S., Leite C.M.S. The systems containing clays and clay minerals from modified drug release: a review. Colloids Surf. B: Biointerfaces 2013, 103:642-651.
42. Seema, Datta M. Clay-polymer nanocomposites as a novel drug carrier: synthesis, characterization and controlled release study of propranolol hydrochloride. Appl. Clay Sci. 2013, 80-81:85-92.
43. Seki Y., Yurdakoc K. Equilibrium, kinetics and thermodynamic aspects of promethazine hydrochloride sorption by iron rich smectite. Colloids Surf. A Physicochem. Eng. Asp. 2009, 340:143-148.
44. Senthil A., Thakkar H.R., Kumar V.D.M. Design and optimization of mucoadhesive microspheres of venlaflaxine HCl using 23 full factorial designs. Pharm. Lett. 2011, 3:202-211.
45. Soppimatha K.S., Aminabhavia T.M., Kulkarnia A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
46. Suresh R., Borkar S.N., Sawant V.A., Shende V.S., Dimble S.K. Nano clay drug delivery system. Int. J. Pharm. Sci. Nanotechnol. 2010, 3(2):901-905.
47. Tang J., Bian Z., Hu J., Xu S., Liu H. The effect of a P123 template in mesopores of mesocellular foam on the controlled-release of venlafaxine. Int. J. Pharm. 2012, 424:89-97.
48. Vilar G., Tulla-Puche J., Albericio F. Polymers and drug delivery systems. Curr. Drug Deliv. 2012, 9.
49. Wang X., Yumin D., Luo J. Biopolymer/montmorillonite nanocomposite: preparation drug-controlled release property and cytotoxicity. Nanotechnology 2008, 19:6570.
50. Ying P., Jie L., Jing L., Yin F., Jiangnan D., Weisan P. Optimization of thermosensitive chitosan hydrogels for the sustained delivery of venlafaxine hydrochloride. Int. J. Pharm. 2013, 441:482-490.
51. Yuan Q., Shah J., Hein S., Misra R.D.K. Controlled and extended drug release behavior of chitosan-based nanoparticle carrier. Acta Biomater. 2010, 6:1140-1148.
52. Zampori L., Stampino P.G., Cristiani C., Cazzola P., Dotelli G. Intercalation of poly(ethylene-oxides) in montmorillonite: tailor-made nanocontainers for drug delivery systems. Appl. Clay Sci. 2010, 50:266-270.
53. Zhao L., Du J., Duan Y., Zang Y., Zhang H., Yang C., Cao F., Zhai G. Curcumin loaded mixed micelles composed of pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf. B: Biointerfaces 2012, 97:101-108. (s).